Outset Medical to Report Fourth Quarter and Full Year 2022 Financial Results on Monday, February 13, 2023

Rhea-AI Summary

Outset Medical, Inc. (NASDAQ: OM) will release its financial results for Q4 and full year 2022 on February 13, 2023, post-market. A conference call hosted by CEO Leslie Trigg and CFO Nabeel Ahmed will take place at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the outcomes. Outset's innovative Tablo® Hemodialysis System aims to transform dialysis by simplifying operations and making care accessible in various settings. The system integrates water purification and on-demand dialysate production, enhancing the dialysis experience for patients.

Positive

• Anticipation of Q4 and full-year financial results.
• Innovative Tablo® Hemodialysis System simplifies dialysis operations.

Negative

• None.

SAN JOSE, Calif.--(BUSINESS WIRE)-- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Monday, February 13, 2023.

On the same day, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) Leslie Trigg, Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Monday, February 13, 2023. Those interested in listening to the conference call may do so by registering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005011/en/

Jim Mazzola

Vice President, Investor Relations

jmazzola@outsetmedical.com

Brian Johnston

Gilmartin Group

investors@outsetmedical.com

Source: Outset Medical, Inc.

FAQ

When will Outset Medical release its Q4 2022 financial results?

Outset Medical will release its Q4 2022 financial results on February 13, 2023.

What time is the Outset Medical conference call?

The conference call is scheduled for 2:00 p.m. Pacific Time on February 13, 2023.

Who will be hosting the conference call for Outset Medical?

The conference call will be hosted by CEO Leslie Trigg and CFO Nabeel Ahmed.

What is the Tablo® Hemodialysis System?

The Tablo® Hemodialysis System is an innovative technology designed to simplify dialysis and reduce costs.